391 related articles for article (PubMed ID: 26829503)
1. Predictive factors of relapse in low-risk gestational trophoblastic neoplasia patients successfully treated with methotrexate alone.
Couder F; Massardier J; You B; Abbas F; Hajri T; Lotz JP; Schott AM; Golfier F
Am J Obstet Gynecol; 2016 Jul; 215(1):80.e1-7. PubMed ID: 26829503
[TBL] [Abstract][Full Text] [Related]
2. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia.
Lybol C; Sweep FC; Harvey R; Mitchell H; Short D; Thomas CM; Ottevanger PB; Savage PM; Massuger LF; Seckl MJ
Gynecol Oncol; 2012 Jun; 125(3):576-9. PubMed ID: 22410329
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for second-line dactinomycin failure after methotrexate treatment for low-risk gestational trophoblastic neoplasia: a retrospective study.
Hoeijmakers YM; Sweep F; Lok C; Ottevanger PB
BJOG; 2020 Aug; 127(9):1139-1145. PubMed ID: 32141676
[TBL] [Abstract][Full Text] [Related]
4. Second Uterine Curettage and the Number of Chemotherapy Courses in Postmolar Gestational Trophoblastic Neoplasia: A Randomized Controlled Trial.
Hemida R; Vos EL; El-Deek B; Arafa M; Toson E; Burger CW; van Doorn HC
Obstet Gynecol; 2019 May; 133(5):1024-1031. PubMed ID: 30969220
[TBL] [Abstract][Full Text] [Related]
5. [Curative effects and influenced factors of primary chemotherapy with single-agent methotrexate on low-risk gestational trophoblastic neoplasia].
Wu XD; Chen LL; Shen T; Chen SS; Chen QQ; Qin JL; Fu YF; Lü WG
Zhonghua Yi Xue Za Zhi; 2017 Jun; 97(23):1769-1772. PubMed ID: 28647996
[No Abstract] [Full Text] [Related]
6. [Effects of primary chemotherapy with single methotrexate on low-risk gestational trophoblastic neoplasia and influencing factors thereof].
Chen YX; Shen YM; Qian JH; Xie X
Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2109-12. PubMed ID: 16313819
[TBL] [Abstract][Full Text] [Related]
7. A retrospective study to evaluate single agent methotrexate treatment in low risk gestational choriocarcinoma in the United Kingdom.
Taylor F; Short D; Winter MC; Tidy J; Savage PM; Sarwar N; Hancock BW; Seckl MJ; Coleman RE
Gynecol Oncol; 2015 Feb; 136(2):258-63. PubMed ID: 25542400
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience.
Maestá I; Nitecki R; Horowitz NS; Goldstein DP; de Freitas Segalla Moreira M; Elias KM; Berkowitz RS
Gynecol Oncol; 2018 Jan; 148(1):161-167. PubMed ID: 29092742
[TBL] [Abstract][Full Text] [Related]
9. Mortality rate of gestational trophoblastic neoplasia with a FIGO score of ≥13.
Bolze PA; Riedl C; Massardier J; Lotz JP; You B; Schott AM; Hajri T; Golfier F
Am J Obstet Gynecol; 2016 Mar; 214(3):390.e1-8. PubMed ID: 26433171
[TBL] [Abstract][Full Text] [Related]
10. Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias.
You B; Pollet-Villard M; Fronton L; Labrousse C; Schott AM; Hajri T; Girard P; Freyer G; Tod M; Tranchand B; Colomban O; Ribba B; Raudrant D; Massardier J; Chabaud S; Golfier F
Ann Oncol; 2010 Aug; 21(8):1643-1650. PubMed ID: 20154304
[TBL] [Abstract][Full Text] [Related]
11. Gestational trophoblastic neoplasia after human chorionic gonadotropin normalization in a retrospective cohort of 7761 patients in France.
Descargues P; Hajri T; Massardier J; Lotz JP; Devouassoux-Shisheboran M; Allias Montmayeur F; You B; Golfier F; Bolze PA
Am J Obstet Gynecol; 2021 Oct; 225(4):401.e1-401.e9. PubMed ID: 34019886
[TBL] [Abstract][Full Text] [Related]
12. The influence of lung metastases on the clinical course of gestational trophoblastic neoplasia: a historical cohort study.
Vree M; van Trommel N; Kenter G; Sweep F; Ten Kate-Booij M; Massuger L; Lok C
BJOG; 2016 Oct; 123(11):1839-45. PubMed ID: 26456952
[TBL] [Abstract][Full Text] [Related]
13. Significance of chest computed tomography findings in the evaluation and treatment of persistent gestational trophoblastic neoplasia.
Gamer EI; Garrett A; Goldstein DP; Berkowitz RS
J Reprod Med; 2004 Jun; 49(6):411-4. PubMed ID: 15283046
[TBL] [Abstract][Full Text] [Related]
14. Serum hCG level and rising world health organization score at second-line chemotherapy (pulse dactinomycin): poor prognostic factors for methotrexate-failed low-risk gestational trophoblastic neoplasia.
Kang WD; Kim CH; Cho MK; Kim JW; Cho HY; Kim YH; Choi HS; Kim SM
Int J Gynecol Cancer; 2010 Nov; 20(8):1424-8. PubMed ID: 21051988
[TBL] [Abstract][Full Text] [Related]
15. Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study.
Braga A; Paiva G; Ghorani E; Freitas F; Velarde LGC; Kaur B; Unsworth N; Lozano-Kuehne J; Dos Santos Esteves APV; Rezende Filho J; Amim J; Aguiar X; Sarwar N; Elias KM; Horowitz NS; Berkowitz RS; Seckl MJ
Lancet Oncol; 2021 Aug; 22(8):1188-1198. PubMed ID: 34181884
[TBL] [Abstract][Full Text] [Related]
16. Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia.
Winter MC; Tidy JA; Hills A; Ireson J; Gillett S; Singh K; Hancock BW; Coleman RE
Gynecol Oncol; 2016 Dec; 143(3):565-570. PubMed ID: 27756557
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Second-Line 5-Day Dactinomycin in Case of Methotrexate Failure for Gestational Trophoblastic Neoplasia.
Prouvot C; Golfier F; Massardier J; You B; Lotz JP; Patrier S; Devouassoux M; Schott AM; Hajri T; Bolze PA
Int J Gynecol Cancer; 2018 Jun; 28(5):1038-1044. PubMed ID: 29629964
[TBL] [Abstract][Full Text] [Related]
18. Validation of an online tool for early prediction of the failure-risk in gestational trophoblastic neoplasia patients treated with methotrexate.
Dekeister K; Bolze PA; Tod M; Tod R; Massardier J; Lotz JP; Hajri T; Colomban O; Seckl MJ; Osborne R; Freyer G; Golfier F; You B
Cancer Chemother Pharmacol; 2020 Jul; 86(1):15-24. PubMed ID: 32500221
[TBL] [Abstract][Full Text] [Related]
19. Does a human chorionic gonadotropin level of over 20,000 IU/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia?
Braga A; Biscaro A; do Amaral Giordani JM; Viggiano M; Elias KM; Berkowitz RS; Seckl MJ
Eur J Obstet Gynecol Reprod Biol; 2018 Apr; 223():50-55. PubMed ID: 29477553
[TBL] [Abstract][Full Text] [Related]
20. Validation of the Predictive Value of Modeled Human Chorionic Gonadotrophin Residual Production in Low-Risk Gestational Trophoblastic Neoplasia Patients Treated in NRG Oncology/Gynecologic Oncology Group-174 Phase III Trial.
You B; Deng W; Hénin E; Oza A; Osborne R
Int J Gynecol Cancer; 2016 Jan; 26(1):208-15. PubMed ID: 26569059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]